[go: up one dir, main page]

IS7081A - Lyfjablanda - Google Patents

Lyfjablanda

Info

Publication number
IS7081A
IS7081A IS7081A IS7081A IS7081A IS 7081 A IS7081 A IS 7081A IS 7081 A IS7081 A IS 7081A IS 7081 A IS7081 A IS 7081A IS 7081 A IS7081 A IS 7081A
Authority
IS
Iceland
Prior art keywords
composition
Prior art date
Application number
IS7081A
Other languages
English (en)
Other versions
IS2347B (is
Inventor
Gaik-Lim Khoo Cynthia
Gustafsson Helena
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0102069A external-priority patent/SE0102069D0/xx
Priority claimed from SE0201660A external-priority patent/SE0201660D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7081A publication Critical patent/IS7081A/is
Publication of IS2347B publication Critical patent/IS2347B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
IS7081A 2001-06-21 2003-12-16 Lyfjablanda til inntöku um munn sem felur í sér jóta-karragen, eina eða fleiri hlutlausar hlaupkenndar fjölliður og basískan lyfjafræðilegan efnisþátt; þar sem blandan tálmar losun basíska lyfjafræðilega virka efnisþáttarins úr blöndunni við súrt pH- IS2347B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0102069A SE0102069D0 (sv) 2001-06-21 2001-06-21 Pharmaceutical formulation
SE0104049 2001-11-30
SE0201660A SE0201660D0 (sv) 2002-05-31 2002-05-31 Pharmaceutical formulation
PCT/SE2002/001217 WO2003000293A1 (en) 2001-06-21 2002-06-19 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
IS7081A true IS7081A (is) 2003-12-16
IS2347B IS2347B (is) 2008-03-15

Family

ID=27354711

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7081A IS2347B (is) 2001-06-21 2003-12-16 Lyfjablanda til inntöku um munn sem felur í sér jóta-karragen, eina eða fleiri hlutlausar hlaupkenndar fjölliður og basískan lyfjafræðilegan efnisþátt; þar sem blandan tálmar losun basíska lyfjafræðilega virka efnisþáttarins úr blöndunni við súrt pH-

Country Status (31)

Country Link
US (1) US7700582B2 (is)
EP (1) EP1401502B1 (is)
JP (1) JP2005501024A (is)
KR (1) KR20040011542A (is)
CN (1) CN1518462A (is)
AR (1) AR034517A1 (is)
AT (1) ATE314093T1 (is)
AU (1) AU2002345463B2 (is)
BG (1) BG108516A (is)
BR (1) BR0210489A (is)
CA (1) CA2450449A1 (is)
CO (1) CO5550466A2 (is)
CZ (1) CZ299859B6 (is)
DE (1) DE60208369T2 (is)
DK (1) DK1401502T3 (is)
EE (1) EE200400028A (is)
ES (1) ES2254699T3 (is)
HU (1) HUP0400850A3 (is)
IL (2) IL159217A0 (is)
IS (1) IS2347B (is)
MX (1) MXPA03011546A (is)
MY (1) MY130332A (is)
NO (1) NO20035627D0 (is)
NZ (1) NZ530086A (is)
PL (1) PL366432A1 (is)
RU (1) RU2323006C2 (is)
SI (1) SI1401502T1 (is)
SK (1) SK286238B6 (is)
UA (1) UA77959C2 (is)
WO (1) WO2003000293A1 (is)
ZA (1) ZA200309316B (is)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
MXPA04004544A (es) * 2001-11-13 2005-03-31 Yamanouchi Pharma Tech Inc Sistema de liberacion prolongada para droga soluble.
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) * 2003-11-28 2003-11-28 Astrazeneca Ab New process
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (en) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2006046954A1 (en) * 2004-10-26 2006-05-04 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
ITMI20050391A1 (it) * 2005-03-11 2006-09-12 Ph & T S P A Formulazioni a rilascio controllato di alfuzosin
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
HRP20110094T8 (en) * 2007-02-01 2011-07-31 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and pioglitazone
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
SI2262486T1 (sl) 2008-08-01 2013-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Sestavek kvetiapina
AR076907A1 (es) * 2009-05-13 2011-07-20 Wyeth Llc Composiciones con liberacion rapida de farmaco
MX2012006240A (es) 2009-12-02 2012-10-03 Aptalis Pharma Ltd Microcapsulas de fexofenadina y composiciones que contienen las mismas.

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
CA1341029C (en) 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
TW201303B (is) * 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
CZ333492A3 (en) 1991-11-12 1993-09-15 Lilly Co Eli Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5760235A (en) 1992-03-04 1998-06-02 Gyogyszerkutato Intezet Kft. Anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for preparation thereof
TW223629B (is) * 1992-03-06 1994-05-11 Hoffmann La Roche
US5780631A (en) * 1993-06-03 1998-07-14 Astra Aktiebolag Starting materials in the synthesis of thrombin and kininogenase inhibitors
SE9301912D0 (sv) * 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
AU1025795A (en) 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) * 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
KR100388185B1 (ko) * 1995-02-17 2003-11-28 애보트 게엠베하 운트 콤파니 카게 트롬빈 억제제로서의 신규 디펩티드 아미딘
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
JP2000514788A (ja) 1996-06-25 2000-11-07 イーライ・リリー・アンド・カンパニー 抗凝固剤
SE9602646D0 (sv) * 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) * 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
IL141688A0 (en) * 1998-09-04 2002-03-10 Scios Inc Hydrogel compositions for the controlled release administration of growth factors
SE9804313D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New compounds
DK1150996T3 (da) * 1999-01-13 2008-02-11 Astrazeneca Ab Nye amidinobenzylaminderivater og deres anvendelse som thrombin-inhibitorer
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
SE0001803D0 (sv) * 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
SE0102921D0 (sv) 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) 2003-11-28 2003-11-28 Astrazeneca Ab New process
GB0503672D0 (en) 2005-02-23 2005-03-30 Astrazeneca Ab New process
GB0510546D0 (en) 2005-05-24 2005-06-29 Astrazeneca Ab New process
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
HUP0400850A3 (en) 2010-10-28
WO2003000293A1 (en) 2003-01-03
CA2450449A1 (en) 2003-01-03
ATE314093T1 (de) 2006-01-15
BR0210489A (pt) 2004-06-22
MY130332A (en) 2007-06-29
NZ530086A (en) 2005-09-30
IL159217A0 (en) 2004-06-01
HUP0400850A2 (hu) 2004-08-30
EP1401502A1 (en) 2004-03-31
EP1401502B1 (en) 2005-12-28
CZ20033491A3 (en) 2004-03-17
RU2323006C2 (ru) 2008-04-27
JP2005501024A (ja) 2005-01-13
US7700582B2 (en) 2010-04-20
AR034517A1 (es) 2004-02-25
SK15912003A3 (sk) 2004-05-04
MXPA03011546A (es) 2004-03-19
SK286238B6 (sk) 2008-06-06
SI1401502T1 (sl) 2006-06-30
CO5550466A2 (es) 2005-08-31
EE200400028A (et) 2004-04-15
US20040242536A1 (en) 2004-12-02
IL159217A (en) 2009-02-11
AU2002345463B2 (en) 2007-08-30
UA77959C2 (en) 2007-02-15
RU2003136155A (ru) 2005-05-20
DE60208369T2 (de) 2006-08-24
BG108516A (en) 2004-12-30
DE60208369D1 (de) 2006-02-02
IS2347B (is) 2008-03-15
CZ299859B6 (cs) 2008-12-17
ES2254699T3 (es) 2006-06-16
NO20035627D0 (no) 2003-12-15
DK1401502T3 (da) 2006-04-10
KR20040011542A (ko) 2004-02-05
PL366432A1 (en) 2005-01-24
ZA200309316B (en) 2005-02-28
CN1518462A (zh) 2004-08-04

Similar Documents

Publication Publication Date Title
IS6915A (is) Lyfjablanda
FI20010780A0 (fi) Parannetut koostumukset
DE60227853D1 (de) Substituierte Pyridinylamine
DE50204184D1 (de) Espressobrüheinrichtung
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
BR0210619A (pt) composição
DE50103741D1 (de) Welle-Nabe-Verbindung
IS7081A (is) Lyfjablanda
DE50206892D1 (de) Substituierte imidazotriazinone
ATE335486T1 (de) Hydrazono-malonitrile
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
DE50203984D1 (de) Kugelgelenk
DE50203412D1 (de) Schwenkkolbenverdränger
ATE355059T1 (de) Isoxazolopyridinone
DE50213651D1 (de) Substituierte 4-aminocyclohexanole
DE50203093D1 (de) Losradlager
ATA18372001A (de) Gelenksbolzenbaueinheit
ATE319694T1 (de) Phenylalkyne
ITTO20020744A0 (it) Composizione
DE50202088D1 (de) Garmodulsystem
ATA13992002A (de) Schlackengranulierungsanlage
ITTO20020745A0 (it) Composizione
DE50108381D1 (de) Synchronisierschaltungsanordnung
DE10295006D2 (de) Bauwerksabdichtung
DE60200786D1 (de) Feste zusammensetzung